002589 瑞康医药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.2780.374-28.2241.7453.570
总资产报酬率 ROA (%)0.0940.116-8.1870.4480.820
投入资产回报率 ROIC (%)0.1220.149-11.0480.6551.257

边际利润分析
销售毛利率 (%)12.04410.29413.58218.22918.381
营业利润率 (%)1.307-1.576-13.9412.3703.509
息税前利润/营业总收入 (%)3.966-0.035-11.2214.4095.593
净利润/营业总收入 (%)0.9200.398-14.1231.8142.296

收益指标分析
经营活动净收益/利润总额(%)-18.347152.26717.889109.154102.622
价值变动净收益/利润总额(%)20.497-132.86752.29744.80415.230
营业外收支净额/利润总额(%)-8.0816.4851.565-7.324-4.284

偿债能力分析
流动比率 (X)1.0941.0721.0281.2521.255
速动比率 (X)0.9920.9680.9521.1271.116
资产负债率 (%)63.65166.26468.62763.27967.281
带息债务/全部投入资本 (%)54.49257.04062.53958.498--
股东权益/带息债务 (%)82.72674.63259.40469.58955.068
股东权益/负债合计 (%)55.16349.20242.98145.30134.543
利息保障倍数 (X)1.439-0.021-3.8152.0032.510

营运能力分析
应收账款周转天数 (天)171.946176.438210.502205.2050.000
存货周转天数 (天)53.14751.78751.13652.3200.000